Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma Clinical Trial

— ERASMM  

Official title:

A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06183489
• Other study ID #: EMN34/2023-505775-70-00
• Status: Recruiting
• Phase: Phase 2
• Start date: May 14, 2024
• Est. completion date: July 2031

Study information

• Verified date: June 2024
• Source: Stichting European Myeloma Network
• Contact: Silvia Villa
• Phone: +31 107033123
• Email: silvia.villa[@]emn.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 2031
• Est. primary completion date: July 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. >18 years of age

2. Diagnosis of SMM for =5 years with measurable disease, defined as serum M protein:

=1g/dL or urine M protein =200 mg/24 hours or involved serum FLC =100 mg/Land abnormal serum FLC ratio.

3. BMPCs =10% and <60%

4. Presence of at least 2 high risk factors, including

1. Serum M protein =2 g/dL,

2. BMPC >20%

3. Serum involved/uninvolved FLC ratio > 20

5. ECOG performance status score of 0 or 1

6. Subjects must meet the following laboratory parameters, per laboratory reference range (performed at most 15 days before cycle 1 day 1)

1. Absolute neutrophil count =1.0 x 109/L (ie, =1000/µL)

2. Platelet count =75 x 109/L

3. Aspartate aminotransferase (AST) =2.5 x upper limit of normal (ULN)

4. Alanine aminotransferase (ALT) =2.5 x ULN

5. Total bilirubin =1.5 x ULN, except in subjects with congenital bilirubinemia,such as Gilbert syndrome (in which case direct bilirubin =2.0 x ULN is required)

7. Subject must sign an informed consent form (ICF) or their legally acceptable representative must sign indicating that he or she understands the purpose of, and procedures required for the study and is willing to participate in the study.

8. Women of childbearing potential must have a negative serum or urine pregnancy test at screening and before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (One highly effective method and one additional effective method) used at the same time, and continuing for at least 5 months after the last dose of Elranatamab. Women must also agree to notify pregnancy during the study.

Exclusion Criteria:

1. Previous therapy with any systemic therapy for multiple myeloma.

2. Evidence of any of the following calcium, renal failure, anemia, bone lesions (CRAB) criteria or Myeloma Defining Events (SLiM CRAB) detailed below (attributable to the participants SMM involvement):

1. Increased calcium levels: Corrected serum calcium >1 mg/dL above the ULN or >11 mg/dL

2. Renal insufficiency: Determined by glomerular filtration rate (GFR) <40 mL/min/1.73 m² (Modification of Diet in Renal Disease [MDRD] Formula) or serum creatinine >2 mg/dL

3. Anemia (hemoglobin 2 g/dL below lower limit of normal or <10 g/dL or both) transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted

4. = 1 bone lytic lesion

5. BMPCs =60%

6. Serum involved/uninvolved FLC ratio =100 and an involved FLC =100mg/L

7. Whole body magnetic resonance imaging (WB-MRI) or positron emission tomography-computed tomography (PET-CT) with more than 1 bone focal lesion (=5 mm in diameter)

3. Diagnosis of primary amyloidosis, POEMS syndrome, monoclonal gammopathy of undetermined significance, symptomatic multiple myeloma, or solitary plasmacytoma.

4. Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.

5. Subject has had plasmapheresis within 14 days of elegibility confirmation.

6. Myocardial infarction within 6 months prior to enrolment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities

7. Ongoing Grade 2 or higher peripheral sensory/motor peripheral neuropathy (PN), history of GBS or GBS variants, or history of grade 3 or higher peripheral motor polyneuropathy

8. Subject has had major surgery within 2 weeks before elegibility confirmation or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study.

9. Clinically relevant active infection or serious co-morbid medical conditions

10. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years.

11. Female subject who is pregnant or breast-feeding

12. Serious medical or psychiatric illness likely to interfere with participation in study

13. Uncontrolled diabetes mellitus

14. Known HIV infection; Known active hepatitis B or C viral infection; known active COVID-19/SARS-CoV-2 infection

15. Live attenuated vaccine administered within 4 weeks of the first dose of study intervention

16. Ongoing treatment with corticosteroids : dose >10mg prednisone etc.

17. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Smoldering Multiple Myeloma

Intervention

Drug:
• Elranatamab
Elranatamab will be administered via a subcutaneous injection (SC)

Locations

Country	Name	City	State
Finland	Helsinki University Hospital	Helsinki
France	CHD Vendée	La Roche-sur-Yon
France	CHRU de Lille - Hopital Claude Huriez	Lille
France	CHU Saint Eloi Département d'Hématologie Clinique	Montpellier
France	CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE	Nantes
France	CHU NICE - Hôpital Archet	Nice
France	CHU Poitiers - Pôle régional de Cancérologie	Poitiers
France	CHRU Hôpital Bretonneau	Tours
Greece	Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens	Athens
Italy	AOU Consorziale Policlinico di Bari	Bari
Italy	A.O. Papa Giovanni XXIII	Bergamo
Italy	A.O.U. Careggi	Firenze
Italy	A.O.U. Policlinico S. Martino - Ematologia	Genova
Italy	Meldola-Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)	Meldola
Italy	Ospedale Papardo	Messina
Italy	A.O.U. Maggiore della Carità Novara	Novara
Italy	A.O. di Padova	Padova
Italy	A.O.U. di Parma - U.O Ematologia e CTMO	Parma
Italy	Fondazione IRCCS Policlinico S. Matteo	Pavia
Italy	Ospedale Santo Spirito Ospedale -Azienda Sanitaria Locale Di Pescara	Roma
Italy	Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale	Udine
Netherlands	Maastricht UMC	Maastricht
Netherlands	St. Antonius Ziekenhuis	Nieuwegein
Netherlands	Erasmus MC	Rotterdam
Norway	Oslo Myeloma Center	Oslo

Sponsors (2)

Lead Sponsor	Collaborator
Stichting European Myeloma Network	Pfizer

Countries where clinical trial is conducted

Finland,  France,  Greece,  Italy,  Netherlands,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Remission (CR) rate	Response of CR is defined as participants who achieve a CR or better (CR+sCR) according to IMWG response criteria, during the first 6 cycles of treatment and before a possible early termination of the treatment	average 24 weeks
Secondary	Overall response rate (ORR)	Overall response rate (ORR) is defined as the proportion of participants achieving a confirmed PR or better according to the IMWG response criteria.	average 24 weeks
Secondary	MRD-negative CR (MRD_CR)	MRD-negative CR (MRD_CR) is defined as the proportion of participants achieving a MRD negativity (at or below the threshold of 10-5 by NGS) and CR or better according to the IMWG response criteria.	average 24 weeks
Secondary	Progression-free survival (PFS)	defined as the time from the date of 1st dose of study drug to the date of first confirmed PD, as defined in the IMWG response criteria, or death due to any cause, whichever occurs first. If the participant is alive and w/o progression disease, the participant's data will be censored at the date of last disease assessment.	time from the date of 1st dose to to the date of disease progression or death, assed up to 4 years after last dose
Secondary	Time to progression (TTP)	Time to progression (TTP) is defined as the time from the date of 1st dose of study drug to the date of first documented PD, as defined in the IMWG response criteria. If the participant is w/o progression disease or die, the participant's data will be censored at the date of last disease assessment.	time from the date of 1st dose to progression or death, assed up to 4 years after last dose
Secondary	Progression free survival 2 (PFS2)	Progression free survival 2 (PFS2) is defined as the time from the date of 1st dose of study drug to the date of event, which is defined as death from any cause or PD as assessed by investigator that starts after the next line of therapy, whichever occurs first. If the participant starts next line of subsequent therapy without disease progression on study treatment, participant's data will be censored at the last disease assessment before starting next line of therapy. If participant starts next line of therapy after progression on study treatment and is still alive and not yet progress on next line of therapy, participant's data will be censored on the last date of follow-up.	time from the date of 1st dose to progression on the next line of treatment or death,assed up to 4 years after last dose
Secondary	Overall survival (OS)	Overall survival (OS) is defined as the time from the date of 1st dose of study drug to the date of death. If the participant is alive, the participant's data will be censored at the date the participant was last known to be alive	time from the date of 1st dose to date of death, assed up to 4 years after last dose
Secondary	Time to response (TTR)	Time to response (TTR) is defined as the time from the date of 1st dose of study drug to the first documented response (=PR). If the participant is alive, w/o progression disease and w/o documented response (=PR), the participant's data will be censored at the date of last disease assessment. If the participant have a progression or die before a documented response (=PR), the participant's data will have a competing event at the date of PFS event.	time frrom the date of 1st dose to the first documented response
Secondary	Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30)	The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-ofLife (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.	from screening, cycle 1 and every 3 cycles there after up to end of treatment and 28 days after last treatment
Secondary	Change in EORTC QLQ- 20-item Multiple Myeloma module (MY-20) score	The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in subjects with MY. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment,Future Perspective, and Body Image. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.	from screening, cycle 1 and every 3 cycles there after up to end of treatment and 28 days after last treatment